-
The Food and Drug Administration (FDA) granted approval, on May 23, 2007, to a generic formulation of zidovudine capsules, 100 mg, manufactured by Cipla Limited, of Mumbai, India.
-
Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance.
-
The debate surrounding the relative merits of abstinence and fidelity vs. condom use (as if the two were mutually exclusive) remains a hotly contested issue, at least in the United States, where it has even spilled over into U.S. international family planning policy.
-
Actg 328 was a multicenter trial that studied HIV-1 infected adults without active AIDS-defining illnesses and with CD4+ lymphocyte counts between 50 and 350/uL. Patients were protease inhibitor (PI) and IL-2 naïve but may have received prior nucleoside analogue therapy.
-
More than two million people living with HIV/AIDS in low and middle income countries now have access to antiretroviral therapy (ART), according to a recent report.
-
-
The most commonly documented interventions made by pharmacists caring for emergency department patients included provision of drug information, dosage adjustment recommendations, responses to questions from nursing staff, formulary interchanges, and suggestions on initiating drug therapy, researchers found.
-
A 25-bed critical access hospital that wanted to improve pharmacy services through use of automated dispensing machines and remote pharmacist review of orders found telepharmacy could help it achieve its objectives, a researcher found.
-
A new web site developed by the Health Systems Pharmacy Executive Alliance identifies best practices for improving health system pharmacy operations and recommendations for adopting the practices.
-
